These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 25209722)

  • 21. Patient-reported outcomes in relapsed ovarian cancer: results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone.
    Krasner CN; Poveda A; Herzog TJ; Vermorken JB; Kaye SB; Nieto A; Claret PL; Park YC; Parekh T; Monk BJ
    Gynecol Oncol; 2012 Oct; 127(1):161-7. PubMed ID: 22765965
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trabectedin for the therapy of ovarian cancer.
    Evangelisti G; Barra F; D'Alessandro G; Tantari M; Stigliani S; Della Corte L; Bifulco G; Ferrero S
    Drugs Today (Barc); 2020 Oct; 56(10):669-688. PubMed ID: 33185631
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-world experience with trabectedin for the treatment of recurrent ovarian cancer.
    Romero I; López-Guerrero JA; Pignata S
    Expert Rev Anticancer Ther; 2021 Oct; 21(10):1089-1095. PubMed ID: 34128757
    [No Abstract]   [Full Text] [Related]  

  • 24. Trabectedin for the treatment of relapsed ovarian cancer.
    Papaioannou D; Rafia R; Stevenson MD; Stevens JW; Evans P
    Health Technol Assess; 2011 May; 15 Suppl 1():69-75. PubMed ID: 21609655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of trabectedin plus pegylated liposomal doxorubicin for the treatment of women with relapsed platinum-sensitive ovarian cancer in the UK: analysis based on the final survival data of the OVA-301 trial.
    Fisher M; Gore M
    Value Health; 2013 Jun; 16(4):507-16. PubMed ID: 23796284
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trabectedin for the management of soft-tissue sarcoma.
    Boudou L; Baconnier M; Blay JY; Lombard-Bohas C; Cassier PA
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):727-37. PubMed ID: 19496709
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The efficacy of trabectedin in treating ovarian cancer.
    Teplinsky E; Herzog TJ
    Expert Opin Pharmacother; 2017 Feb; 18(3):313-323. PubMed ID: 28140689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors.
    Chu Q; Mita A; Forouzesh B; Tolcher AW; Schwartz G; Nieto A; Soto-Matos A; Alfaro V; Lebedinsky C; Rowinsky EK
    Clin Cancer Res; 2010 May; 16(9):2656-65. PubMed ID: 20406837
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis.
    Lebedinsky C; Gómez J; Park YC; Nieto A; Soto-Matos A; Parekh T; Alfaro V; Roy E; Lardelli P; Kahatt C
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1223-31. PubMed ID: 21416137
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer.
    Jones RL; Herzog TJ; Patel SR; von Mehren M; Schuetze SM; Van Tine BA; Coleman RL; Knoblauch R; Triantos S; Hu P; Shalaby W; McGowan T; Monk BJ; Demetri GD
    Cancer Med; 2021 Jun; 10(11):3565-3574. PubMed ID: 33960681
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies.
    Machiels JP; Staddon A; Herremans C; Keung C; Bernard A; Phelps C; Khokhar NZ; Knoblauch R; Parekh TV; Dirix L; Sharma S
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):729-37. PubMed ID: 25100135
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies.
    von Mehren M; Schilder RJ; Cheng JD; Temmer E; Cardoso TM; Renshaw FG; Bayever E; Zannikos P; Yuan Z; Cohen RB
    Ann Oncol; 2008 Oct; 19(10):1802-9. PubMed ID: 18497430
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-World Outcomes of Combination Chemotherapy with Trabectedin plus Pegylated Liposomal Doxorubicin in Patients with Recurrent Ovarian Cancer: A Single-Center Experience.
    Moriceau G; Rivoirard R; Méry B; Vallard A; Pacaut C; Trone JC; Espenel S; Bosacki C; Jacquin JP; Magné N
    Chemotherapy; 2016; 61(3):122-6. PubMed ID: 26752402
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimizing treatment of the partially platinum-sensitive ovarian cancer patient.
    Colombo N
    Future Oncol; 2013 Dec; 9(12 Suppl):19-23. PubMed ID: 24195526
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval.
    Kaye SB; Colombo N; Monk BJ; Tjulandin S; Kong B; Roy M; Chan S; Filipczyk-Cisarz E; Hagberg H; Vergote I; Lebedinsky C; Parekh T; Santabárbara P; Park YC; Nieto A; Poveda A
    Ann Oncol; 2011 Jan; 22(1):49-58. PubMed ID: 20643863
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer.
    Del Campo JM; Roszak A; Bidzinski M; Ciuleanu TE; Hogberg T; Wojtukiewicz MZ; Poveda A; Boman K; Westermann AM; Lebedinsky C;
    Ann Oncol; 2009 Nov; 20(11):1794-802. PubMed ID: 19556318
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety evaluation of trabectedin in treatment of soft-tissue sarcomas.
    Martin-Liberal J; Judson I
    Expert Opin Drug Saf; 2013 Nov; 12(6):905-11. PubMed ID: 23937190
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment with trabectedin: should be indicated to all soft tissue sarcoma histotypes?
    Grivas A; Trafalis DT; Thanopoulou E; Ziras NG; Athanasiou AE
    J BUON; 2010; 15(4):791-3. PubMed ID: 21229647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-World Management of Trabectedin/Pegylated Liposomal Doxorubicin in Platinum-Sensitive Recurrent Ovarian Cancer Patients: A National Survey.
    Ferrandina G; Amadio G; Paris I; Distefano M; Palluzzi E; de Vincenzo R; Ricci C; Scambia G
    Int J Gynecol Cancer; 2017 Jul; 27(6):1141-1148. PubMed ID: 28574933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens.
    Krasner CN; McMeekin DS; Chan S; Braly PS; Renshaw FG; Kaye S; Provencher DM; Campos S; Gore ME
    Br J Cancer; 2007 Dec; 97(12):1618-24. PubMed ID: 18000504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.